NetScientific appoints Dr François R. Martelet as Chief Executive Officer

13-May-2015 - United Kingdom

NetScientific announces the appointment of Dr François R. Martelet as Chief Executive Officer and Board Director.

Dr Martelet will join the Group on 8 June 2015. Sir Richard Sykes, who has been Executive Chairman prior to this appointment, will revert to his position as Non-Executive Chairman.

Most recently, Dr Martelet has served as senior advisor to the CEO and Interim SVP at Stallergenes SA where he was responsible for international commercial strategies. During this period, sales revenues grew by 20+% and various new products were launched, including Oralair®, into ex-US markets. Before this, he was CEO at Topotarget A/S, a publicly traded European biotech company specialised in oncology therapeutics which he successfully transformed from a research based organisation into a late-stage clinical development company ready for a European exit.

Prior to this, Dr Martelet served as CEO of Avax Technologies Inc., a US biotech company specialised in therapeutic oncology vaccines. He has also held senior level commercial positions at Merck & Co, Inc. (VP & Global Franchise Head-Oncology), Novartis Pharma (SVP & Head of Central & Eastern Europe, Middle East and Africa), Schering-Plough and Eli Lilly.

https://www.bionity.com/en/news/152819/netscientific-appoints-dr-francois-r-martelet-as-chief-executive-officer.html